Latest News by Industry
Demonstrated Long-term Clinical Benefit of Govorestat in ACTION-Galactosemia Kids Trial
Strengthened Balance Sheet with $30 Million Private Placement of Equity
Phase 3 INSPIRE Trial of Govorestat in Sorbitol Dehydrogenase (SORD) Deficiency and ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy on Track for Data in 2023
NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the first quarter ended March 31, 2023.
“We are committed to bringing transformative therapies to patients with debilitating diseases and no treatment options, including Galactosemia, SORD Deficiency and Diabetic Cardiomyopathy,” said Shoshana Shendelman, PhD, Founder and CEO of Applied Therapeutics. “We look forward to discussing our recent Galactosemia data with regulatory agencies and potentially moving towards approval of govorestat for Galactosemia later this year. We are also excited about our upcoming data readouts in SORD Deficiency and Diabetic Cardiomyopathy. Our recent financing helps to strengthen the balance sheet to support advancement of our clinical programs towards commercialization.”
Recent Highlights
Financial Results
About Applied Therapeutics
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Galactosemia, SORD Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.
To learn more, please visit www.appliedtherapeutics.com and follow the company on Twitter @Applied_Tx.
Forward-Looking Statements
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) our plans to request a pre-NDA meeting or submit an NDA or MAA for approval and (ii) the anticipated cash runway of the Company. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.
Such risks and uncertainties include, without limitation, (i) our plans to develop, market and commercialize our product candidates, (ii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iii) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (iv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (v) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vi) our ability to maintain and establish collaborations or obtain additional funding, (vii) our ability to obtain and timing of regulatory approval of our current and future product candidates, (viii) the anticipated indications for our product candidates, if approved, (ix) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (x) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, (xi) the implementation of our business model and strategic plans for our business and product candidates, (xii) our intellectual property position and the duration of our patent rights, (xiii) developments or disputes concerning our intellectual property or other proprietary rights, (xiv) our expectations regarding government and third-party payor coverage and reimbursement, (xv) our ability to compete in the markets we serve, (xvi) the impact of government laws and regulations and liabilities thereunder, (xvii) developments relating to our competitors and our industry, (xvii) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xiv) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Contacts
Investors:
Maeve Conneighton
(212) 600-1902 or
appliedtherapeutics@argotpartners.com
Media:
media@appliedtherapeutics.com
| Applied Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share data) | ||||||||
| As of | As of | |||||||
| March 31, | December 31, | |||||||
| 2023 | 2022 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 22,917 | $ | 16,657 | ||||
| Investments | — | 13,923 | ||||||
| Prepaid expenses and other current assets | 6,146 | 6,728 | ||||||
| Total current assets | 29,063 | 37,308 | ||||||
| Operating lease right-of-use asset | 743 | 857 | ||||||
| Security deposits and leasehold improvements | 198 | 198 | ||||||
| TOTAL ASSETS | $ | 30,004 | $ | 38,363 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Current portion of operating lease liabilities | $ | 483 | $ | 477 | ||||
| Accounts payable | 5,555 | 4,534 | ||||||
| Accrued expenses and other current liabilities | 14,025 | 14,756 | ||||||
| Warrant liability | 13,188 | 13,657 | ||||||
| Total current liabilities | 33,251 | 33,424 | ||||||
| NONCURRENT LIABILITIES: | ||||||||
| Noncurrent portion of operating lease liabilities | 291 | 414 | ||||||
| Clinical holdback - long-term portion | 534 | 464 | ||||||
| Total noncurrent liabilities | 825 | 878 | ||||||
| Total liabilities | 34,076 | 34,302 | ||||||
| STOCKHOLDERS’ EQUITY: | ||||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 48,113,561 shares issued and outstanding as of March 31, 2023 and 48,063,358 shares issued and outstanding as of December 31, 2022 | 5 | 5 | ||||||
| Preferred stock, par value $0.0001; 10,000,000 shares authorized as of March 31, 2023 and December 31, 2022; 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022 | - | - | ||||||
| Additional paid-in capital | 354,883 | 352,828 | ||||||
| Accumulated other comprehensive gain/(loss) | — | 51 | ||||||
| Accumulated deficit | (358,960 | ) | (348,823 | ) | ||||
| Total stockholders' equity | (4,072 | ) | 4,061 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 30,004 | $ | 38,363 | ||||
| Applied Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2023 | 2022 | |||||||
| REVENUE: | ||||||||
| License Revenue | $ | 10,660 | $ | — | ||||
| Total Revenue | 10,660 | — | ||||||
| OPERATING EXPENSES: | ||||||||
| Research and development | $ | 15,935 | $ | 15,030 | ||||
| General and administrative | 5,583 | 8,071 | ||||||
| Total operating expenses | 21,518 | 23,101 | ||||||
| LOSS FROM OPERATIONS | (10,858 | ) | (23,101 | ) | ||||
| OTHER INCOME (EXPENSE), NET: | ||||||||
| Interest income | 221 | 76 | ||||||
| Change in fair value of warrant liabilities | 469 | — | ||||||
| Other expense | 31 | (96 | ) | |||||
| Total other income, net | 721 | (20 | ) | |||||
| Net loss | $ | (10,137 | ) | $ | (23,121 | ) | ||
| Net loss attributable to common stockholders—basic and diluted | $ | (10,137 | ) | $ | (23,121 | ) | ||
| Net loss per share attributable to common stockholders—basic and diluted | $ | (0.18 | ) | $ | (0.88 | ) | ||
| Weighted-average common stock outstanding—basic and diluted | 56,357,983 | 26,215,514 | ||||||